CNS PHARMACEUTICALS INC
CNSPNASDAQ🏆 #3780 by market capUS Equity
$473.01▲ $30.37 (+6.42%)
Simulated price1h—
24h▲ 6.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
62
Fair
No chart data available for CNSP.
Trading Snapshot
- Day Range
- $469.71 – $478.59
- 52-Week Range
- $1.90 – $10.59
- Volume
- $1.80B
- Avg Volume
- $2.11B
- Shares Outstanding
- 1.5M
- Next Earnings
- Sep 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $780,962
- Last Q Revenue
- $211,327
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-29.17
- Dividend Yield
- —
Why Investors Own CNSP
- ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$780,962▼ −9.6% YoY
Gross Margin (TTM)
52.7%▲ +3.5% YoY
Operating Income (TTM)
$242,098▼ −9.6% YoY
Free Cash Flow (TTM)
$217,107▼ −9.6% YoY
About CNS PHARMACEUTICALS INC
A company profile for CNS PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
62/100
Analyst Price Target
ⓘAverage Target
$485.03
▲ +2.5% Upside
High Target$562.10
Low Target$445.46
Based on 27 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
CNS PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift CNSP price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
CNS PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.